<circle stroke="#1e77f9" class="srdi68r9" cx="25" cy="25" r="20" fill="none" stroke-width="5">

Trump Weekly: Trump signs pharma order, FTC opens inquiry into AI chatbots

GLUE

PremiumThe Fly

6d ago

PremiumThe Fly

Microsoft, OpenAI sign MOU for next phase of partnership: Morning Buzz

6d ago

PremiumThe Fly

Molson Coors downgraded, GM upgraded: Wall Street’s top analyst calls

6d ago

PremiumThe FlyNovartis downgraded to Sell from Neutral at Goldman Sachs

6d ago

Novartis AG Faces Sell Rating Amid Overvaluation and Looming Generic Competition

Ratings

Novartis AG Faces Sell Rating Amid Overvaluation and Looming Generic Competition

6d ago

Advertising, drugmaker stocks in spotlight as Trump moves to regulate pharma ads

The Fly

Advertising, drugmaker stocks in spotlight as Trump moves to regulate pharma ads

8d ago

Omnicom, WPP under pressure after Trump moves to regulate pharma ads

PremiumThe Fly

8d ago

Trump Trade: U.S. President signs new pharma order

BMY

PremiumThe Fly

8d ago

Trump signs memorandum mandating pharma ads give more info on risks

PremiumThe Fly

9d ago

Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz

BMY

PremiumThe Fly

9d ago

PremiumThe FlyTourmaline Bio to be acquired by Novartis for $48.00 per share in cash

9d ago

TRML

Novartis price target raised to CHF 105 from CHF 100 at Morgan Stanley

The Fly

Novartis price target raised to CHF 105 from CHF 100 at Morgan Stanley

10d ago

Novartis AG: Balancing Promising Pipeline Developments with Valuation and Risk Concerns

Ratings

Novartis AG: Balancing Promising Pipeline Developments with Valuation and Risk Concerns

14d ago

Oppenheimer says Olema collaboration with Pfizer could lead to bidding war

PremiumThe Fly

15d ago

Argo announces new strategic collaboration with Novartis

PFE

PremiumThe Fly

15d ago

Arrowhead, Novartis announce licensing and collaboration agreement for ARO-SNCA

PremiumThe Fly

16d ago

Novartis’ Leqvio shows statistically significant LDL-C goal achievement in study

ARWR

PremiumThe Fly

19d ago

PremiumCompany AnnouncementsExelixis and Novartis: Key Updates from the Pan Tumor Rollover Study

22d ago

EXEL

Novartis, BioArctic enter collaboration and license pact for BrainTransporter

The Fly

Novartis, BioArctic enter collaboration and license pact for BrainTransporter

23d ago

Novartis and Incyte’s Ruxolitinib Study: A Potential Game-Changer for Myelofibrosis Treatment

Company Announcements

Novartis and Incyte’s Ruxolitinib Study: A Potential Game-Changer for Myelofibrosis Treatment

27d ago